Cargando…
境外授权许可引进抗肿瘤新药临床研发策略的审评考虑
With the boom of China's innovative pharmaceutical industry, licensing-in model has gradually become an important research and development model for innovative pharmaceutical companies. The in-licensed drugs at different stages need different research and development (R & D) strategy in Chi...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346151/ https://www.ncbi.nlm.nih.gov/pubmed/35899440 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.27 |
Ejemplares similares
-
罕见肿瘤新药研发的思考
Publicado: (2022) -
研究者发起的临床研究用于支持新药研发面临的挑战
Publicado: (2022) -
MUC16:肿瘤治疗新靶点
Publicado: (2022) -
非小细胞肺癌新辅助免疫治疗进展
Publicado: (2022) -
腺苷/A2AR信号通路阻断在肿瘤治疗中的应用
Publicado: (2022)